ERBB2 and breast carcinoma: The specificity and synergistic effects of these dual-aptamer-decorated nanoparticles were rigorously assessed through confocal microscopy and cell viability assays on various human cell types, including TNBC cell lines, luminal/HER2-positive breast cancer cells, epidermoid carcinoma cells, and adipose-derived mesenchymal stromal/stem cells, and preclinical 3D stroma-rich breast cancer models, consisting of either 3D spheroids cocultures of tumor cells and MSCs, and breast cancer organoids derived from pathologically and molecularly well-characterized human tumors.